Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2011-002507-15
    Sponsor's Protocol Code Number:GS-US-259-0116
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2012-01-11
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2011-002507-15
    A.3Full title of the trial
    A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Ranolazine on Major Adverse Cardiovascular Events in Subjects with a History of Chronic Angina Who Undergo Percutaneous Coronary Intervention with Incomplete Revascularization
    Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, de los efectos de la ranolazina sobre los principales acontecimientos cardiovasculares adversos en sujetos con antecedentes de angina crónica que se someten a intervención coronaria percutánea con revascularización incompleta
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A placebo controlled, randomized clinical study to evaluate whether ranolazine can prevent death, heart attacks, or hospitalization for chest pain in patients with a history of chest pain who had a procedure to open up blockages in blood vessels feeding the heart, but still have some blockages left untreated.
    Ensayo clínico aleatorizado, controlado con placebo, para evaluar si ranolazina puede prevenir la muerte, ataques al corazón u hospitalización por dolor de pecho en pacientes con historial de dolor de pecho operados para abrir las obstrucciones en los vasos sanguíneos que riegan el corazón, pero que aún tienen algunas obstrucciones sin resolver.
    A.4.1Sponsor's protocol code numberGS-US-259-0116
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorGilead Sciences, Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportGilead Sciences, Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationGilead Sciences International Limited
    B.5.2Functional name of contact pointClinical Trials Information
    B.5.3 Address:
    B.5.3.1Street AddressFlowers Building, Granta Park
    B.5.3.2Town/ cityGreat Abington, Cambridge
    B.5.3.3Post codeCB21 6GT
    B.5.3.4CountryUnited Kingdom
    B.5.4Telephone number+441223897 496
    B.5.5Fax number+441223897 284
    B.5.6E-mailclinical.trials@gilead.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Ranexa 500 mg prolonged-release tablets
    D.2.1.1.2Name of the Marketing Authorisation holderMenarini International Operations Luxembourg S.A.
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Prolonged-release tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNRANOLAZINE
    D.3.9.1CAS number 95635-55-5
    D.3.9.4EV Substance CodeSUB10259MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number500
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Coronary artery disease
    Enfermedad arterial coronaria
    E.1.1.1Medical condition in easily understood language
    Heart disease
    Enfermedad cardiaca
    E.1.1.2Therapeutic area Diseases [C] - Cardiovascular Diseases [C14]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.1
    E.1.2Level PT
    E.1.2Classification code 10011078
    E.1.2Term Coronary artery disease
    E.1.2System Organ Class 10007541 - Cardiac disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of this study is to evaluate the efficacy of ranolazine as compared with placebo when used as part of standard medical therapy in chronic angina subjects with incomplete
    revascularization post-PCI on the incidence of MACE, defined as the composite of CV death, MI, or hospitalization for ischemia or angina.
    Evaluar la eficacia de ranolazina en comparación con placebo sobre la incidencia de acontecimientos cardiovasculares adversos graves (ACAG), definidos como la combinación de muerte cardiovascular (CV), infarto de miocardio (IM) y hospitalización por isquemia o angina de pecho, al emplearse como parte del tratamiento médico estándar de sujetos con angina crónica y revascularización incompleta post- intervención coronaria percutánea (ICP)
    E.2.2Secondary objectives of the trial
    The secondary objectives of this study are to:
    - Evaluate the efficacy of ranolazine as compared with placebo when used as part of standard medical therapy in chronic angina subjects with incomplete revascularization post-PCI on the incidence of the individual components of the primary endpoint
    - Evaluate the efficacy of ranolazine as compared with placebo when used as part of standard medical therapy in chronic angina subjects with
    incomplete revascularization post-PCI on the incidence of:
    - repeat revascularization for ischemia or angina
    - sudden cardiac death
    - Assess quality of life (QoL) in the ranolazine group as compared to the placebo group at Month 1, 6 and 12
    - Assess the pharmacoeconomic benefit of ranolazine post-PCI
    - Evaluate the tolerability and safety of ranolazine post-PCI
    -Evaluar la eficacia de ranolazina en comparación con placebo sobre la incidencia de los componentes individuales del criterio de valoración principal al emplearse como parte del tratamiento estándar en sujetos con angina crónica y revascularización incompleta post-ICP
    -Evaluar la eficacia de ranolazina en comparación con placebo sobre la incidencia de repetición de la revascularización por isquemia o angina al emplearse como parte del tratamiento estándar en sujetos con angina crónica y revascularización incompleta post-ICP
    -Evaluar la eficacia de ranolazina en comparación con placebo sobre la incidencia de muerte súbita cardíaca al emplearse como parte del tratamiento estándar en sujetos con angina crónica y revascularización incompleta post-ICP
    -Valorar la calidad de vida (CdV) en el grupo de ranolazina en comparación con el grupo placebo en el mes 1, 6 y 12
    -Valorar el beneficio farmacoeconómico de ranolazina post-ICP
    -Evaluar tolerabilidad y seguridad de ranolazina post-ICP
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    Integrated Quality of Life and Health Economics Sub-Study. Date/Version: 18Jul2011

    Health Economics sub-study current planned for US only.

    Quality of Life sub-study is planned globally.
    Integrated Quality of Life and Health Economics Sub-Study. Fecha/Version: 18Jul2011

    El subestudio Health Economics actualmente está planeado para US solamente.

    El subestudio Quality of Life sub-study está planeado de forma global.
    E.3Principal inclusion criteria
    1. Written informed consent
    2. Males and females aged 18 years and older
    3. History of chronic angina defined as at least 2 episodes of anginal pain or discomfort precipitated by exertion and relieved by rest or sublingual nitroglycerin which occurred on at least 2 separate days between 30 days to 1 year prior to PCI (in the case of staged PCI procedures, at least 30 days prior to the first PCI in the series). Subjects may have additional angina episodes in the 30 days prior to their first PCI in the series, as well as anytime prior to randomization.
    4. PCI for ACS, defined as hospitalization for anginal pain/discomfort within the previous 24 hours to their hospitalization with any one (or more) of the following criteria:
    i. Elevated troponin or creatinine kinase-MB (CK-MB) consistent with MI, as reported by local laboratory and measured prior to index PCI
    ii. Electrocardiographic changes comprising new or presumably new ST segment depression ? 0.1 mV (? 1 mm), or ST segment elevation ? 0.1 mV (? 1 mm) in at least 2 contiguous leads, or new or presumably new Left Bundle Branch Block

    -OR-

    PCI for any reason other than ACS, with at least one of the following:
    i. Previous CABG surgery
    ii. Previous PCI (in the case of staged PCI, a previous PCI must predate the first PCI in the staged series)
    iii. History of multivessel CAD (? 50% stenosis in 2 or more epicardial coronary arteries, whether previously treated or untreated)
    iv. Pharmacologically treated (not diet only or pancreatic transplant) type 1 or type 2 DM
    5. Post-PCI (post the last PCI for staged procedures) evidence of incomplete revascularization defined as the presence of a visually estimated ? 50% stenosis in one or more coronary arteries with reference vessel diameter of at least 2.0 mm, whether in the target vessel or in a non target vessel, (in the case of a subject post-CABG, incomplete revascularization is defined as the presence of an unbypassed ? 50% stenosis in an epicardial vessel ? 2.0 mm in diameter, or ? 50% stenosis in a bypass graft supplying an otherwise
    unrevascularized myocardial territory)
    6. Clinically stable and with a CK-MB < 3 times the upper limit of normal (ULN) at least 8 hours post-PCI, or if ? 3 times the ULN with evidence of decreasing CK-MB (decreased by at least 20% from the prior measure), as reported by local laboratory. If CK-MB is not available, a subject must have evidence of normal or decreasing troponin levels (decreased by at least 20% from the prior measure) at
    least 8 hours post-PCI, as reported by local laboratory. For subjects who
    are randomized following hospital discharge and who have not had at least one cardiac biomarker (CK-MB or troponin I or T) measured post-PCI, at least one cardiac marker (CK-MB or troponin I or T) will be measured and reported per the local laboratory. Randomization may occur prior to receipt of the cardiac marker test results.
    7. Ability and willingness to comply with all study procedures during the course of the study
    8. Females of childbearing potential must have a negative pregnancy test at Screening (unless surgically sterile or post-menopausal) and must agree to use highly effective contraception methods from Screening throughout the duration of study treatment and for 14 days following the last dose of study drug.
    1.Consentimiento informado por escrito
    2. Hombres y mujeres de 18 años o más
    3. Antecedentes de angina crónica definidos como un mínimo de 2 episodios de dolor o malestar por angina de pecho, que se potencian durante el ejercicio y se reducen con reposo o nitroglicerina sublingual, y que tienen lugar en al menos 2 días diferentes entre 30 días y 1 año antes de la ICP (en el caso de los procedimientos de ICP por etapas, 30 días antes, como mínimo, de la primera ICP de la serie). Los sujetos pueden sufrir episodios de angina de pecho adicionales en los 30 días previos al primer procedimiento de la ICP de la serie, así como en cualquier momento previo a la aleatorización.
    4. ICP para el SCA, definida como hospitalización por dolor/malestar por angina de pecho en las 24 horas previas a la hospitalización con cualquiera (uno o más de uno) de los siguientes criterios:
    i. Troponina o creatinina quinasa-MB (CK-MB) elevadas compatibles con IM, conforme a la notificación del laboratorio local y medidas antes de la ICP inicial
    ii.Alteraciones electrocardiográficas que impliquen depresión nueva, tanto real como posible, del segmento ST ? 0,1 mV (? 1 mm) o, elevación del segmento ST ? 0,1 mV (? 1 mm) en, como mínimo, 2 derivaciones
    contiguas, o bloqueo nuevo, tanto real como posible, de la rama izquierda
    -O-
    ICP por cualquier razón que no sea SCA con, como mínimo, uno de las siguientes:
    i. Cirugía CABG previa
    ii. ICP previa (en el supuesto de ICP por etapas, la fecha de la ICP previa debe ser anterior a la primera ICP de la serie por etapas)
    iii. Antecedentes de enfermedad coronaria (EC) de múltiples vasos (estenosis del ? 50 % en 2 o más arterias coronarias epicárdicas, ya sea con tratamiento previo o sin él)
    iv. Diabetes mellitus (DM) tipo 1 o 2 tratada farmacológicamente (no con dieta únicamente ni con trasplante pancreático)
    5. Evidencia post-ICP (posterior a la última ICP para procedimientos por etapas) de revascularización incompleta definida como la presencia de una estenosis ? 50 %, estimada de forma visual, en una o más arterias coronarias, con un diámetro de referencia del vaso de, al menos, 2,0 mm , en el vaso diana o otro vaso que no sea el vaso diana,(en el supuesto de un sujeto post-CABG, la revascularización incompleta se define como la presencia de una estenosis ? 50 % en un vaso epicárdico sin bypass de ? 2,0 mm de diámetro, o una estenosis ? 50 % en una derivación por injerto, que irrigan una sección del miocardio que, de no existir, quedaría sin revascularizar)
    6. Estable clínicamente y con CK-MB < 3 veces el límite superior de normalidad (ULN, por sus siglas en inglés), al menos 8 horas post-ICP o, si ? 3 veces el ULN con evidencia de reducción de CK-MB (reducción, como mínimo, del 20 % con respecto a la medida anterior), conforme a la información proporcionada por el laboratorio local. Si no se dispone de CK-MB, un sujeto debe mostrar evidencias de niveles normales o disminuidos de troponina (como mínimo, del 20 % con respecto a la medida anterior), durante, al menos, 8 horas post-ICP, conforme a la información proporcionada por el laboratorio local. A los sujetos que son aleatorizados tras el alta hospitalaria y a losque no se les ha medido, al menos, un biomarcador cardíaco (CK-MB o troponina I o T) post-ICP, el laboratorio local les medirá al menos un marcador cardíaco (CK-MB o troponina I o T) y enviará el informe. La aleatorización puede tener lugar antes de recibir los resultados del análisis del marcador cardíaco.
    7. Capacidad y voluntad de cumplir los procedimientos del estudio durante el trascurso del mismo.
    8. Las mujeres con capacidad de concebir deben tanto presentar una prueba de embarazo negativa en la selección (a menos que estén esterilizadas quirúrgicamente o en la posmenopausia), como aceptar el uso de métodos anticonceptivos altamente efectivos desde la selección hasta 14 días después de la administración de la última dosis del fármaco en estudio. Véase la sección 8.7 para obtener una descripción de los métodos anticonceptivos aceptables así como una definición de posmenopausia.
    E.4Principal exclusion criteria
    1. Any future planned revascularization (including staged procedures) or possible planned revascularization (ie, planned stress test to assess need for additional revascularization). Subjects may be enrolled after the last PCI in the staged series or once a decision is made not to perform a follow up PCI, as long as randomization occurs within 14 daysfrom the last PCI.
    2. Unrevascularized left main coronary artery stenosis ? 50%
    3. Major complication during or after the index PCI (in the case of staged PCI, the last in the series) including:
    i. Major bleeding (TIMI Bleeding classification or any bleeding requiring ? 2 units of red blood cells)
    ii. Coronary perforation requiring treatment
    iii. Procedural complication requiring surgery (including CABG or peripheral vascular surgery)
    4. Stroke within 90 days prior to PCI, or any history of stroke with permanent major neurologic disability (eg, aphasia or significant motor dysfunction)
    5. Cardiogenic shock within 90 days prior to Randomization
    6. New York Heart Association (NYHA) Class III or IV heart failure
    7. Estimated GFR < 30 mL/min/1.73m2 using the 4 variable modification of diet in renal disease (MDRD) equation, per local laboratory
    8. Liver cirrhosis
    9. Use of Class Ia, Ic, and Class III antiarrhythmics, except for amiodarone
    10. Current treatment with potent inhibitors of CYP3A
    11. Current treatment with CYP3A4 inducers or P-gp inducers
    12. Subjects taking simvastatin who cannot reduce the dose to 20 mg once daily or who cannot switch to another statin
    13. Previous treatment with ranolazine within 30 days prior to Screening, or known hypersensitivity or intolerance to ranolazine
    14. Participation in another investigational drug or device study within 30 days prior to Screening (participation in registries is allowed)
    15. Women who are pregnant or breast feeding
    16. Comorbid conditions limiting life expectancy to < 12 months
    17. Any condition that in the opinion of the investigator would preclude compliance with the study protocol.
    1. Cualquier revascularización futura, tanto planificada (incluyendo procedimientos por etapas) como posible (es decir, prueba de esfuerzo planificada para valorar la necesidad de una revascularización adicional). Se podrá inscribir a los sujetos después de la última ICP de la serie por etapas o una vez que estos hayan tomado la decisión de no someterse a la ICP de seguimiento, siempre que la aleatorización tenga lugar en los 14 días siguientes a la última ICP.
    2. Estenosis del tronco de la arteria coronaria izquierda sin revascularizar ? 50 %.
    3. Complicación grave durante o tras la ICP inicial (en caso de que se trate de ICP por etapas, la última de la serie), que incluye
    i. Hemorragia grave (según la escala de clasificación de la hemorragia TIMI [Apéndice 5] o cualquier hemorragia que requiera una transfusión de sangre ? 2 unidades de hematíes)
    ii. Perforación coronaria que requiera tratamiento
    iii. Complicación en el procedimiento que requiera cirugía (incluyendo CABG o cirugía vascular periférica)
    4. Ictus en los 90 días previos a la ICP, o cualquier antecedente de ictus con discapacidad neurológica grave permanente (p. ej. afasia o disfunción motora significativa)
    5. Choque cardiógeno en los 90 días previos a la aleatorización.
    6. Insuficiencia cardíaca clase III o IV según la Asociación Cardiológica de Nueva York (New York Heart Association, NYHA).
    7. Una tasa de filtración glomerular (GFR) estimada <30 ml/min/1,73 m2, utilizando la ecuación derivada del estudio de modificación de la dieta en enfermedad renal (MDRD), en su versión de 4 variables (Apéndice 8), facilitada por el laboratorio local.
    8. Cirrosis hepática.
    9. Utilización de antiarrítmicos de clase Ia, Ic y clase III, excepto amiodarona (conforme se describe en el Apéndice 4).
    10. Tratamiento actual con inhibidores potentes de CYP3A (conforme se describe en el Apéndice 3).
    11. Tratamiento actual con inductores del CYP3A4 o inductores de la glicoproteína P (gp-P) (conforme se describe en el Apéndice 3).
    12. Los sujetos que reciben simvastatina que no puedan reducir la dosis a 20 mg una vez al día o que no puedan pasar a otra estatina.
    13. Tratamiento previo con ranolazina en los 30 días anteriores a la selección o con hipersensibilidad conocida o intolerancia a ranolazina.
    14. Participación en otro estudio de un dispositivo o fármaco en investigación en los 30 días previos a la selección (la participación en registros está permitida).
    15. Mujeres embarazadas o en lactancia.
    16. Afecciones comórbidas que limitan la esperanza de vida a < 12 meses.
    17. Cualquier afección que, según la opinión del investigador, impidiera cumplir el protocolo del estudio.
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy endpoint is the incidence of MACE, defined as the
    composite of:
    ? CV death, or
    ? MI, or
    ? Hospitalization for ischemia or angina
    El criterio de valoración principal de la eficacia es la incidencia de ACAG, que se definen como la combinación de:
    ? Muerte CV, o
    ? IM, u
    ? Hospitalización por isquemia o angina
    E.5.1.1Timepoint(s) of evaluation of this end point
    The primary endpoints will be adjudicated throughout the study by the Clinical Events Committee.
    Los criterios de valoración primarios se adjudicarán a lo largo del estudio por un Comité de acontecimientos clínicos
    E.5.2Secondary end point(s)
    Secondary endpoints will include:
    ? Hospitalization for ischemia or angina
    ? Repeat revascularization for ischemia or angina
    ? Sudden cardiac death
    ? CV death
    ? MI
    ? Hospitalización por isquemia o angina
    ? Repetición de la revascularización por isquemia o angina
    ? Muerte súbita cardíaca
    ? Muerte CV
    ? IM
    E.5.2.1Timepoint(s) of evaluation of this end point
    The secondary points will be adjudicated throughout the study by the Clinical Events Committee.
    Los criterios de valoración secundarios se adjudicarán a lo largo del estudio por un Comité de acontecimientos clínicos
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned9
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA90
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Austria
    Belgium
    Canada
    Czech Republic
    France
    Germany
    Israel
    Italy
    Netherlands
    Poland
    Spain
    Sweden
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The study will continue at least 1 year post randomization follow-up has been achieved for all subjects and at least 721 adjudicated first post-randomization major adverse cardiovascular events (CV death, MI, or hospitalization for ischemia or angina) have been observed.

    The end of the study will be reached when the last subject enrolled has completed their final End of Treatment visit.
    Por lo menos, un año tras el reclutamiento del último sujeto y, como mínimo, hasta que se hayan observado 721 acontecimientos adjudicados del criterio de valoración principal
    El ensayo terminará cuando el último paciente enrolado haya completado su última visita de Fin de Tratamiento.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months2
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months2
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 1300
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 1300
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state135
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 1255
    F.4.2.2In the whole clinical trial 2600
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Subjects should continue concomitant antianginal medications and should restart any medications discontinued during the screening period after completion of all study procedures under the care of their primary treating physician.
    Los sujetos deberían continuar el tratamiento concomitante con antianginosos y deberían reanudar cualquier medicación discontinuada durante el perido de screening después de completar todos los procedimientos del estudio bajo el cuidado de su médico de atención primaria
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2012-02-15
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2012-02-07
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2015-02-03
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 18:37:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA